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Abstract
TRIP4 is one of the subunits of the transcriptional coregulator ASC-1, a ribonucleoprotein complex that participates in
transcriptional coactivation and RNA processing events. Recessive variants in the TRIP4 gene have been associated with
spinal muscular atrophy with bone fractures as well as a severe form of congenital muscular dystrophy. Here we present the
diagnostic journey of a patient with cerebellar hypoplasia and spinal muscular atrophy (PCH1) and congenital bone
fractures. Initial exome sequencing analysis revealed no candidate variants. Reanalysis of the exome data by inclusion in the
Solve-RD project resulted in the identification of a homozygous stop-gain variant in the TRIP4 gene, previously reported as
disease-causing. This highlights the importance of analysis reiteration and improved and updated bioinformatic pipelines.
Proteomic profile of the patient’s fibroblasts showed altered RNA-processing and impaired exosome activity supporting the
pathogenicity of the detected variant. In addition, we identified a novel genetic form of PCH1, further strengthening the link
of this characteristic phenotype with altered RNA metabolism.
Introduction
The thyroid receptor interacting protein 4, encoded by the
TRIP4 gene, is one of the four subunits of the transcrip-
tional coregulator ASC-1. TRIP4, together with ASCC1,
ASCC2 and ASCC3, form a ribonucleoprotein complex
that participates in transcriptional coactivation and RNA
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processing events [1]. TRIP4 binds transcription factors,
such as AP-1 and NF-kappa-B through its conserved
cysteine rich Zn-chelating domain [2], whilst the C-
terminal RNA-binding PUA domain is involved in RNA
processing [3].
Recessive variants in TRIP4 have been associated with
two distinct phenotypes: spinal muscular atrophy with bone
fractures (OMIM #616866; ref. [1]) and a severe form of
congenital muscular dystrophy (CMD)(OMIM #617066;
ref. [4, 5]). Interestingly, changes in another subunit of the
transcriptional coregulator ASC-1, ASCC1, also result in a
prenatal muscle weakness with arthrogryposis and con-
genital bone fractures [1, 6]. Since the first reports in 2016
describing the two associated phenotypes, only five addi-
tional CMD families have been reported [5]. Here we pre-
sent the diagnostic journey of a patient with cerebellar
hypoplasia, spinal muscular atrophy (PCH1-like) and con-
genital bone fractures, where we identified a homozygous
stop-gain variant in the TRIP4 gene; the ninth case reported
world-wide.
Subjects and methods
This study was approved by the Ethics Committee of
University of Duisburg-Essen (19-9011-BO). All the
involved subjects gave their written informed consent.
Exome sequencing
DNA from the index case and his parents was subjected to
whole exome sequencing (WES) using Nextera Rapid
Exome Capture (Illumina)(Supplementary material). Exonic
and splice site variants with a minor allele frequency of
<1% in external databases (i.e. ExAC, 1000 genomes) were
prioritized. In silico prediction tools such as Polyphen2
(http://genetics.bwh.harvard.edu/pph2/), CADD (https://ca
dd.gs.washington.edu/) and SIFT (http://sift.jcvi.org/) were
used to assess pathogenicity.
WES reanalysis
The fastq files for the index case and his parents were
submitted to Solve-RD [7] through the Genome-Phenome
Analysis Platform (GPAP, https://platform.rd-connect.eu/)
as part of the European Reference Network for Neuro-
muscular Disease (ERN-EURO-NMD, https://ern-euro-
nmd.eu/), and processed using the RD-Connect bioinfor-
matics pipeline [8]. The reanalysis strategy carried out by
the SNV-Indels Working Group [7, 9] implemented auto-
mated data filtration to specifically identify previously
reported disease-causing variants (as annotated in ClinVar
v.13-01-2020) from a candidate gene list of 594 genes
known to be associated with NMD [9]. The identified var-
iant has been submitted to ClinVar (SUB8878662;
https://www.ncbi.nlm.nih.gov/clinvar).
Mass spectrometry based proteomic analysis
Control and patient-derived fibroblasts were grown to a
70% confluency and mechanically harvested. Label free
shotgun proteomic analysis was performed as previously
described [10]. To interrogate protein-dysregulation path-
ways a Gene Ontology (GO) term analysis was performed.
Proteomaps (www.proteomaps.net) was used to visualise
affected cellular functions. The mass spectrometry pro-
teomics data was submitted to the ProteomeXchange Con-




The patient was the first child of consanguineous parents,
born at 38 weeks of gestational age by Caesarean section
(Apgar score: 5/5/5). Pregnancy was complicated by oli-
gohydramnios, placental insufficiency and growth retarda-
tion. The newborn presented small for gestational age at
birth (weight 2610 g [6th percentile], length 42 cm [<3th
percentile], head circumference 34.5 cm [40th percentile]).
Multiple contractures and intrauterine-originated fractures
of both femurs and the right humerus were present at birth.
He also showed respiratory insufficiency complicated by
absence of spontaneous movements so that invasive venti-
lation was initiated. Clinical course was further char-
acterised by pleural effusion and chylothorax, biliary calculi
and soft tissue emphysema. Cranial and thoracic MRI per-
formed at the age of 6 weeks revealed a hypoplastic cere-
bellum but normal pons, necrosis and haemorrhage of the
occipital cortex, pronounced atrophy of skeletal muscu-
lature and confirmed bilateral pleural effusion (Fig. 1). After
excluding 5q-SMA by genetic analysis of the SMN1 gene, a
vastus lateralis muscle biopsy was performed for further
diagnostic evaluation, yet due to the massive atrophy, the
number of intact fibres was too small to allow a valid
pathological examination. Given the unfavourable prog-
nosis, after consultation with the parents and the clinical
ethical committee, invasive ventilation was terminated at
the age of 8 weeks when the patient died. The combination
of SMA and cerebellar hypoplasia resembled patients with
disease-causing variants in components of the human RNA
exosome [11].
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Initial genetic analysis
SMN1 and additional single-gene screening of ACTA1,
BIN1, DNM2, MTM1, RYR1, SEPN1, TNNT1, TPM2 and
TPM3 was negative. Trio exome sequencing was under-
taken, with the first round of analysis taking place in 2017.
Stringent filtering criteria retrieved no variants in known
disease-causing or strong candidate genes.
Reanalysis of exome data
The ‘low hanging fruit’ strategy implemented in 2020 by
the SNV-Indels Working Group of Solve-RD [7, 9] meant
only variants already known to be associated with disease
were selected. Thus, a homozygous stop-gain variant [hg19:
chr15:64698591 C > T; NM_016213.5:c.760 C > T; p.
(Arg254*)] in the TRIP4 gene was identified. This variant
had been previously reported in three patients (from two
families) with Prenatal Spinal Muscular Atrophy and Con-
genital Bone Fractures [1], proving to be a phenotypic
match and final diagnosis to our patient.
Proteomic findings
To further validate the pathogenicity of the detected variant
and to obtain biochemical insights into the underlying
pathophysiology, a proteomic profile on patient-derived
fibroblasts was carried out. Applying a data independent
acquisition (DIA) approach, a total of 3558 proteins were
quantified. Among these, 323 were significantly dysregu-
lated (p-ANOVA ≤ 0.05): 143 (4.2%) and 180 (5.6%) pro-
teins showed increased and decreased abundance,
respectively. An intersection of dysregulated proteins with
genetic variants revealed no significant correlations. Pro-
teomaps and a GO term analysis revealed a dysregulation of
diverse signaling cascades including the NF-kappa-B
pathway. We also detected an increased abundance in
proteins of the RNA-processing machinery, while decreased
proteins suggested impaired exosomal activity (Fig. 2).
Discussion
We describe the diagnostic journey of a patient presenting
with a cerebellar hypoplasia and SMA (PCH1-like) phe-
notype with bone fractures, in whom the exome reanalysis
using the RD-Connect/Solve-RD pipeline [8, 9] identified a
homozygous stop-gain variant in the TRIP4 gene. Intrigu-
ingly, the disease-causing variant was not found during the
first round of analysis (circa 2017), even though coverage at
this position was >40x. TRIP4 was associated with disease
only in 2016 [1, 4], however the initial WES analysis
searched for candidate variants in the whole exome, and not
just a gene list of known associated genes. Since the TRIP4
variant is a highly deleterious homozygous variant, it seems
unlikely that it would have not been picked as a strong
candidate. In fact, by interrogating filtered VCF files we
speculate that the variant must have been filtered out during
the bioinformatics steps. This emphasises that reevaluation
of legacy exome data should be performed not only by
periodic reiteration of the analysis [12], but also by
improved and updated bioinformatic pipelines, such as
those implemented in Solve-RD [7–9].
TRIP4 encodes a transcription coactivator which facil-
itates nuclear receptors-mediated transcription and
ribosome-associated quality control in mammalian cells
[13]. It has been also shown to play a role in transactivation
of NF-kappa-B [2].
The combination of genomics, transcriptomics and pro-
teomics is increasingly being used to correlate protein
abundances with genetic variants, as well as to delineate
pathways affected by the loss of a functional protein
[14, 15]. Such approaches build on the assumption that
protein interaction networks can be viewed as maps in
which diseases can be identified with characteristic pro-
teomic signatures [14, 16]. Tissues such as blood, skin or
muscle biopsies provide a source of DNA, RNA and protein
[14] suitable to study the molecular etiology of these dis-
eases [10]. Here, we showed how proteomic profiling was
carried out in a patient with PCH1-like disease with bone
Fig. 1 Magnetic resonance imaging (MRI). Cranial and thoracic
MRI performed at the age of 6 weeks revealed a hypoplastic cere-
bellum, necrosis and haemorrhage of the occipital cortex, pronounced
atrophy of skeletal musculature and confirmed bilateral pleural
effusion.
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fractures to evaluate the pathogenicity of the detected var-
iant and to obtain insights into the biochemical etiology.
Our pathway-analyses of proteomic findings highlighted
perturbations in RNA-processing and signaling processes
including the NF-kappa-B pathway. We detected decrease
in abundance of the RNA exosome complexes, in line with
the clinical presentation of PCH1 [17], however no variant
was detected in any of the known genes encoding subunits
or accessory proteins of the human exosome complex.
Although the TRIP4 protein was not detectable on the
proteomics profile, alteration of other proteins resulted in a
“proteomic signature”, highlighting the molecular con-
sequences of the loss of TRIP4. The similar clinical pre-
sentation of patients with variants in TRIP4 and exosomal
Fig. 2 In silico studies of
proteomic data. Gene Ontology
(GO) term analysis was




majority of increased proteins is
involved in RNA processing,
whereas most of decreased
proteins (B) control the response
to oxidative stress or are
involved in protein folding.
“Molecular Function” revealed
that proteins involved in RNA-
binding and modulating
nucleotide binding are increased
(C), and those involved in the
cytoskeleton structure and the
modulation of oxidative stress
predominate amongst the
downregulated (D). “Cellular
Component” showed that the
proteins upregulated in the
patient-derived fibroblasts
mostly belong to the nucleus




pathway analysis also focussed
on increased and decreased
proteins separately. G For
increased proteins, it confirmed
changes in RNA-transport and
RNA-processing, and indicated
an activation of the protein
clearance machinery (Ubiquitin-
mediated proteolysis via the
proteasome) as well as altered
signalling processes (Ras, ErbB
and MAPK pathways). H For







lysosomal as well as exosome
function.
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proteins further highlights that PCH1 is genetically het-
erogeneous, and linked with ribosome dysfunction and
abnormal RNA processing [18].
Clinical and biochemical synopsis
A neurological syndrome combining cerebellar hypoplasia
and spinal motor muscular atrophy is already linked to
exosomal protein variants expanding the list of human
exosomopathies [11]. The RNA exosome represents a
conserved multi-protein complex essential for gene
expression via processing and degradation of mRNA [19].
Proteomic pathway analysis in a patient with a novel TRIP4
variant revealed a dysregulation of RNA-processing and
down-regulation of exosomal proteins. These findings
suggest a common pathomechanism leading to the clinical
manifestation of this neurological syndrome. However,
comparative biochemical studies in in vitro or in vivo
models are crucial to elucidate the precise molecular nature
of the common pathophysiology.
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